Prime Medicine (NASDAQ: PRME) has had a lot to celebrate in recent months, explaining a surge that has seen the prime editing therapy developer’s stock more than double this year, including a 22% jump ...

Enterprise AI needs one thing if it’s to get around the limitations of large language models and deliver the results businesses need from their agents. It doesn’t matter if you’re building ...